Literature DB >> 21674158

Are we ready to move away from nature?: the rapamycin story.

Monica Mita, Alain Mita.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21674158     DOI： 10.1007/s11523-011-0183-8

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  10 in total

Review 1.  Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences.

Authors:  Hakan Cam; Peter J Houghton
Journal:  Target Oncol       Date:  2011-04-16       Impact factor: 4.493

Review 2.  Common toxicities of mammalian target of rapamycin inhibitors.

Authors:  Scott A Soefje; Anand Karnad; Andrew J Brenner
Journal:  Target Oncol       Date:  2011-04-16       Impact factor: 4.493

Review 3.  Mammalian target of rapamycin as a target in hematological malignancies.

Authors:  Kevin R Kelly; Julie H Rowe; Swaminathan Padmanabhan; Steffan T Nawrocki; Jennifer S Carew
Journal:  Target Oncol       Date:  2011-04-17       Impact factor: 4.493

Review 4.  Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Authors:  Zelton Dave Sharp; Arlan Richardson
Journal:  Target Oncol       Date:  2011-03-11       Impact factor: 4.493

Review 5.  Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Authors:  Sumanta Kumar Pal; Robert A Figlin
Journal:  Target Oncol       Date:  2011-04-12       Impact factor: 4.493

Review 6.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Authors:  Sushma Vemulapalli; Alain Mita; Yesid Alvarado; Kamalesh Sankhala; Monica Mita
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

Review 7.  Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.

Authors:  Catherine Delbaldo; Sébastien Albert; Chantal Dreyer; Marie-Paule Sablin; Maria Serova; Eric Raymond; Sandrine Faivre
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

Review 8.  Mechanisms of mTOR inhibitor resistance in cancer therapy.

Authors:  Jennifer S Carew; Kevin R Kelly; Steffan T Nawrocki
Journal:  Target Oncol       Date:  2011-03-09       Impact factor: 4.493

Review 9.  Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.

Authors:  Shin Ogita; Patricia Lorusso
Journal:  Target Oncol       Date:  2011-05-06       Impact factor: 4.493

Review 10.  Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

Authors:  Yesid Alvarado; Monica M Mita; Sushma Vemulapalli; Devalingam Mahalingam; Alain C Mita
Journal:  Target Oncol       Date:  2011-05-04       Impact factor: 4.864
  10 in total
  2 in total

1.  Rapamycin, anti-aging, and avoiding the fate of Tithonus.

Authors:  Arlan Richardson
Journal:  J Clin Invest       Date:  2013-08       Impact factor: 14.808

Review 2.  Effect of rapamycin on aging and age-related diseases-past and future.

Authors:  Ramasamy Selvarani; Sabira Mohammed; Arlan Richardson
Journal:  Geroscience       Date:  2020-10-10       Impact factor: 7.713
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.